{
    "clinical_study": {
        "@rank": "75618", 
        "arm_group": [
            {
                "arm_group_label": "Human Serum Albumin/interferon alpha2a", 
                "arm_group_type": "Experimental", 
                "description": "Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C."
            }, 
            {
                "arm_group_label": "Pegasys", 
                "arm_group_type": "Active Comparator", 
                "description": "Peginteferon 180 mcg multiple dose S.C."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label study that will be conducted at a single site in China to evaluate the\n      safety,tolerability and PK/PD profile of multiple dose of recombinant human serum\n      albumin/interferon alpha2a fusion protein in chronic hepatitis B patients.The total duration\n      of study participation is up to 22 weeks for each subject,including 4 weeks screening\n      period."
        }, 
        "brief_title": "Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 18-75 years\n\n          -  Chronic HBV infection (serum HBsAg detectable for > 6 months)\n\n          -  Serum HBeAg positive with HBV DNA >10^6copies/mL (or >20,000 IU/mL),orSerum HBeAg\n             negative with HBV DNA >10^5copies/mL (or >2,000 IU/mL)\n\n          -  Serum ALT must be > 2 x ULN but below 10 x ULN\n\n        Exclusion Criteria:\n\n          -  Steroid treatment or immunosuppression 3 months prior to entry.\n\n          -  Interferon therapy or nucleotides analogues therapy in 6 months prior to entry.\n\n          -  Active lung disease or history of interstitial lung disease.\n\n          -  Hb< LLN or, and ANC < 750/mm3 or , and platelet count < 75,000 mm3 ,or WBC<3000/mm3 .\n\n          -  Significant chronic medical conditions other than chronic hepatitis B which in the\n             opinion of the investigator preclude enrollment into the study.\n\n          -  Evidence of hepatic decompensation (i.e., Child-Pugh score of B or C).\n\n          -  Seropositive for HIV, HCV, or HDV (Hepatitis Delta virus).\n\n          -  History of thyroid disease or current treatment for thyroid disease.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997944", 
            "org_study_id": "921302"
        }, 
        "intervention": [
            {
                "arm_group_label": "Human Serum Albumin/interferon alpha2a", 
                "description": "600,750 or 900 mcg dosing every 2 weeks", 
                "intervention_name": "Human Serum ALbumin/interferon alpha2a", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Pegasys", 
                "description": "180 mcg dosing every week", 
                "intervention_name": "Pegasys", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "contact": {
                "last_name": "Yanhua Ding, MD", 
                "phone": "+86-431-88782168"
            }, 
            "facility": {
                "address": {
                    "city": "Changchun", 
                    "country": "China", 
                    "state": "Jilin", 
                    "zip": "130021"
                }, 
                "name": "Jilin University First Affiliated Hospital"
            }, 
            "investigator": {
                "last_name": "Yanhua Ding, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase Ib Study of Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Chronic Hepatitis B Patients", 
        "overall_contact": {
            "last_name": "Yanhua Ding, MD", 
            "phone": "+86-431-88782168"
        }, 
        "overall_contact_backup": {
            "last_name": "Junqi Niu, MD", 
            "phone": "+96-431-88782168"
        }, 
        "overall_official": {
            "affiliation": "Jilin University First Affiliated Hospital", 
            "last_name": "Junqi Niu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997944"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Decrease of HBV DNA", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "AUCss", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Css_av", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Css_min", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Css-max", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "T1/2", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }, 
            {
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "18 weeks"
            }
        ], 
        "source": "Beijing Bio-Fortune Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Beijing Bio-Fortune Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}